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The therapeutic effects of Bistrimate2 (sodium bismuth triglycollamate 
(Smith)) were studied over a period of nine months from November 1946 to 
August 1947 under the direction of Dr. Frances Pascher in charge of the treat-
ment unit of the New York Skin and Cancer Unit, New York Post Graduate 
Medical School and Hospital. Four staff members participated in the study and 
their independent observations were used as the basis of this report. A total 
of 92 patients was treated with Bistrimate for periods ranging from four weeks 
to five months. 
The following dermatoses were treated: 
Lupus erythematosus ........................................................ 45 
Discoid ............................................................... 40 
Subacute disseminated........ . .......... . ............................ 2 
Congestive.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 
Telangiectatic....... . . . . . . . . . . . . . . . . . . . . . . . . . . . • . . . . . . . . . . . . . . . . . . . . . 1 
Lichen planus ............... .. ..... . .......................... . ............. 32 
Exanthematic ........................................................ 21 
Hypertrophic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 
Oral.. ......................... . .................. . . . ................. 2 
Granuloma annulare. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 
Scleroderma (diffuse). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
(circumscribed)................................................. 2 
Mosaic wart. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Lichen nitidus ....... , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Mycosis fungoides............. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Parapsoriasis (guttate).... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
(chronic lichenoid)........ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Psoriasis arthropathica............. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 
Keratoderma blenorrhagica............ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
1 From the New York Skin and Cancer Unit, Department of Dermatology and Syphilol-
ogy-New York Post Graduate Medical School and Hospital, Dr. Marion B. Sulzberger, 
Director. 
Received for publication January 23, 1948. 
• We are indebted to Carrol Dunham Smith Pharmacal Co. for the supply of Bistrimate 
for this investigation. 
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RESULTS 
A. Results in lupus erythematosus 
The discoid cases (group of 40) were subdivided into two groups: 
1. Early discoid (duration less than 6 months) 
Healed.................................................................... 1/6 
Improved................................................................. 5/6 
2. Discoid, of long duration (from 7 months to many years) 
Healed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4/34 
Improved............................................................... 21/34 
Unimproved. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7/34 
Relapse................................................................. 2/34 
The results in the other forms of lupus erythematosus treated were: 
Subacute disseminated Improved .......................................... 2/2 
Telangiectatic Unimproved......... . .. .. . . . . .. . .. . .. . .. .. . .. .. . . . . 1/1 
Congestive Improved.......................................... 2/2 
The results for the entire group of lupus erythematosus were as follows: 
Healed ........................................................ . 
Improved ..................................................... . 
Unimproved .................................................. . 
Relapse8 ••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
B. Results in lichen planus 
5/45 or 11+% 
30/45 or 67-% 
8/45 or 17+% 
2/45 or 4+% 
The exanthematic cases (group of 21) were subdivided into two groups: dura-
tion less than or over two months. 
Exanthematic (early) 
Healed............................................................... 1/6 
Improved. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2/6 
Unimproved.......................................................... 3/6 
Exanthematic (over 2 months) 
Healed ................ ; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . 1/15 
Improved............................................................ 5/15 
Unimproved. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4/15 
Worse................................................................ 3/15 
Relapse.............................................................. 2/15 
Other forms of lichen planus treated were: 
Hypertrophic 
Healed................................................................ 0/9 
Improved ............................................................... 5/9 
Buccal 
Unimproved.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4/9 
Unimproved.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2/2 
a Relapse while under treatment. 
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The results for the entire group of lichen planus were as follows: 
Improved or healed..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14/32 or 44-% 
Unimproved.................................................. 14/32 or 43+% 
Worse or relapse.............................................. 4/32 or 12+% 
C. Results in a miscellaneous group of dermatoses 
(}ranuloma annulare ................................ 3 Improved 
{
1 Diffuse-unimproved 
Scleroderma ........................................ 2 Circumscribed-improved 
Mosaic wart ........................................ 1 Improved' 
Lichen nitidus ..................................... {1
1 Uim~roved d 
mmprove 
Mycosis fungoides .................................. 1 Unimproved 
. . {1 (}uttate-improved 
ParapsoriaSIS ....................................... 1 Lichenoid-unimproved 
Psoriasis arthropathica ............................. 3 Unimproved 
Keratoderma blenorrhagica ......................... 1 Unimproved 
COMMENT 
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As a rule the cases that responded favorably to Bistrimate showed improve-
ment in approximately four to six weeks after treatment was started. In most 
cases two to three months were required for the maximum therapeutic effect. 
In three cases improvement continued during the fourth month of treatment 
and in one case of circumscribed scleroderma, resolution continued into the fifth 
month of treatment. The initial dose was one tablet three times a day after 
meals; and the average dose for adults was four to six tablets daily. Each tablet 
contains 410 mg. of sodium bismuth triglycollamate. This is equivalent to 75 
mg. of metallic bismuth. 
A gingival bismuth line appeared in most cases, in some as early as two weeks, 
in others as late as ten to fourteen weeks after therapy was initiated. Treatment 
was not interrupted in these patients unless a stomatitis supervened. A urine 
analysis was done routinely every two to three weeks in the majority of cases. 
Albuminuria was found on one occasion. In twenty-one cases a complete blood 
count was done at biweekly intervals to ascertain whether or not this bismuth 
preparation affects the hemogram. The findings are of interest in view of the 
sparse reports on the effects of bismuth (parenteral as well as oral) on the hemo-
poietic tissues. A leukopenia (less than 4,000 white blood cells per cubic milli-
meter of blood) occurred in four of the 21 cases. In six cases the depression of 
the white blood cells appeared between the sixth and eighth weeks of treatment. 
A relative decrease in the percentage of polymorphonuclear cells and a rise in 
the lymphocyte ratio were also noted. The lowest figure obtained was 2,800 
white cells per cubic millimeter of blood. The depression in the granulocytes 
proved to be transitory, however, since normal levels were obtained two to four 
weeks later despite continuation of therapy. 
'Remarkable improvement after two months of therapy in a seemingly incurable case. 
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The response of the early cases of discoid lupus erythematosus (duration six 
months or less) was uniformly good in the small group studied. The results in the 
more chronic cases varied as the figures indicate. No case was made worse but 
two suffered relapse while under treatment. The results in subacute disseminated 
lupus erythematosus were not satisfactory, although both patients improved to a 
limited extent. Both patients were under treatment for approximately three 
months. Some of the lesions healed, others remained unchanged, and in one 
patient new lesions appeared during the course of treatment. 
The results in lichen planus are rather equivocal, since the number of improved 
and unimproved cases tally. It is interesting to note that the subjective and 
objective changes in lichen planus were not always parallel. In six instances 
of the exanthema tic type, symptomatic improvement (relief of itching) was strik-
ing after a few days. The patients continued to be comfortable while taking 
Bistrimate even though there was no apparent regression in the lesions after four 
or more weeks of continuous treatment. In three of these, lapse of therapy was 
followed by a symptomatic relapse and return of pruritus. 
Treatment was discontinued in 9 cases because of the following untoward 
effects: 
1. Marked stomatitis and trigeminal neuralgia in two cases. The same symp-
toms recurred in one of these patients after the subsequent administration 
of bismuth subsalicylate intramuscularly. 
2. Moderate stomatitis in two cases. 
3. Gastro-intestinal upset in three cases. The patients complained of ab-
dominal pain, nausea, vomiting and diarrhea. 
4. Peripheral neuritis in one case. 
5. Generalized pruritus and toxic erythema after ingestion of five tablets by one 
patient. 
In nineteen cases there was an opportunity to compare the therapeutic ef-
ficacy or oral bismuth (Bistrimate) with parenteral bismuth (bismuth subsali-
cylate in oil intramuscularly). Nine cases failed to respond to either form of 
bismuth, three cases did equally well with both; in three the dermatosis appeared 
to undergo involution faster with the oral preparation; and in four cases that 
had failed to respond to injections of bismuth subsalicylate, oral Bistrimate pro-
duced a therapeutic response. Among these four cases, the response in one was 
fair, in two the response was good, and in one (of discoid lupus erythematosus) 
healing was complete while under Bistrimate therapy. 
CONCLUSIONS 
This therapeutic assay indicates that Bistrimate is a valuable therapeutic 
agent in the treatment of the discoid type of lupus erythematosus. The results in 
this disease may be rated as good to excellent in 50% of the cases, moderate or 
fair in 25%, and poor in 25%. 
It is more difficult to evaluate the efficacy of the drug in the exanthematic 
type of lichen planus, particularly because of the variable course of this disease. 
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Subjective or objective improvement was obtained in 40% of the cases. On 
the other hand 12% grew worse or suffered relapse while under treatment. 
The results are also equivocal in the hypertrophic form of lichen planus. 
The results in the limited number of cases of scleroderma and granuloma an-
nulare allow no inferences but appear to justify further therapeutic investigation. 
In general the drug is tolerated well. Recovery from the apparently mild 
toxic effects was complete within a few days to two weeks in all cases in which 
Bistrimate had to be discontinued because of the untoward reactions herein de-
scribed. 
